J. Dehaven

发表

Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience.

U. Nseyo, J. Dehaven, T. Dougherty, 1998, Journal of clinical laser medicine & surgery.

Keyhole Limpet Hemocyanin Immunotherapy of Bladder Cancer: Laboratory and Clinical Studies

J. Dehaven, D. Lamm, D. Riggs, 2000, European Urology.

Treatment of murine transitional cell carcinoma with intralesional interleukin 2 and murine interferon gamma.

J. Dehaven, D. Lamm, D. Riggs, 1991, The Journal of urology.

Toxic effects of cadmium on the garden snail (Helix aspersa)

J. Dehaven, L. Russell, R. Botts, 1981, Bulletin of environmental contamination and toxicology.

Liposomal delivery of alpha-Interferon to murine bladder tumor cells via transferrin receptor-mediated endocytosis.

Y. Rojanasakul, J. Dehaven, J. Shao, 1998, Drug delivery.

Immunotherapy of murine transitional cell carcinoma of the bladder using alpha and gamma interferon in combination with other forms of immunotherapy.

J. Dehaven, D. Lamm, D. Riggs, 1992, The Journal of urology.

Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer.

J. Dehaven, D. Lamm, A. Kamat, 1999, Urology.

Allium sativum (garlic) treatment for murine transitional cell carcinoma

J. Dehaven, D. Lamm, D. Riggs, 1997, Cancer.

Megadose vitamins in bladder cancer: a double-blind clinical trial.

J. Dehaven, D. Lamm, D. Riggs, 1994, The Journal of urology.

Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH).

J. Dehaven, D. Lamm, R. Ebert, 1993, The Journal of urology.

A cell-based drug delivery system for lung targeting: I. Preparation and pharmacokinetics.

Y. Rojanasakul, J. Dehaven, C. Malanga, 2001, Drug delivery.

Antibiotic and steroid therapy of massive systemic bacillus Calmette-Guerin toxicity.

J. Dehaven, D. Lamm, E. Ting, 1992, The Journal of urology.

A randomized prospective comparison of oral versus intravesical and percutaneous bacillus Calmette-Guerin for superficial bladder cancer.

J. Dehaven, D. Lamm, M. Sarosdy, 1990, The Journal of urology.

Immunotherapy of murine bladder cancer by irradiated tumor vaccine.

J. Dehaven, D. Lamm, R. Bryner, 1991, The Journal of urology.

Suppression of B-cell and T-cell responses by the prostaglandin-induced T-cell-derived suppressor (PITS). II. Resolution of multiple PITS beta factors.

J. Dehaven, T. Rogers, R. Donnelly, 1984, Cellular immunology.

Drug therapy of bacillus Calmette-Guérin sepsis

J. Dehaven, D. Lamm, D. Riggs, 2004, Urological Research.

Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.

J. Dehaven, D. Lamm, M. Sarosdy, 1991, The Journal of urology.

A cell-based drug delivery system for lung targeting: II. Therapeutic activities on B16-F10 melanoma in mouse lungs.

Y. Rojanasakul, J. Dehaven, C. Malanga, 2001, Drug delivery.

Suppression of B-cell and T-cell responses by the prostaglandin-induced T-cell-derived suppressors (PITS)--III. Production of PITS beta factors from T-cell hybridomas.

J. Dehaven, T. Rogers, R. Donnelly, 1985, International journal of immunopharmacology.

Keyhole limpet hemocyanin immunotherapy of murine bladder cancer

J. Dehaven, D. Lamm, R. Burrell, 2004, Urological Research.